Roivant Sciences (United States).
company in New York, United States
- Reports this week
- 1
- Active events
- 1
- Connections
- 78
What's happening
Active this week
Earlier this month
-
Roivant Sciences and Janux Therapeutics are healthcare companies competing for investment.Some support1 report
-
Ramaswamy's financial profile and business interests in Roivant Sciences are being reported amid the Ohio gubernatorial race.Some support1 report
-
Analyst firm Leerink partners raised the price target for Roivant based on share count forecast on August 13, 2025.Well supported4 reports1 development inside
-
Acton's political rivals are contrasting her wealth sources, which stem from a company she founded that is generating wealth.Some support2 reports
One to three months ago
-
Roivant Sciences licensed a drug from Pfizer for regulatory approval.Some support2 reports
-
Roivant Sciences identifies a potential market for its successful drug candidate in Europe.Some support2 reports
-
A drug developed by Roivant/Priovant Therapeutics received FDA approval for the treatment of dermatomyositis.Some support3 reports
-
Roivant Sciences received rating updates and price targets from Bank of America, Citigroup, and Leerink Partners.Some support1 report
-
Roivant Sciences is seeking FDA decisions regarding its registrational trial for LPP, which is ongoing.Some support2 reports
-
Roivant Sciences stock, traded on Nasdaq, saw UBS lift its position and Goldman Sachs grow its holdings, with transactions disclosed in SEC filings.Some support7 reports
Gone quiet
No new reports in 90+ days-
Roivant Sciences and Q32 Bio Inc. are two medical companies currently competing for investment.Some support1 report
-
Roivant Sciences received a buy rating and price targets from Jefferies Financial Group.Some support1 report
-
Roivant filed a 10-Q statement with the SEC on August 12, 2025, while its stock was sliding against a marginally down S&P 500.Some support2 reports
-
Roivant reported financial results from Basel, Switzerland, and hosted a conference call in London.Some support1 report
-
Goldman Sachs resumed coverage of Pulmovant, a Roivant subsidiary, with a 'Buy' rating.Some support2 reports
-
Eric Venker sold shares worth $1,145,000 of Roivant Sciences on June 25, 2025.Speculative1 report
-
Ongoing LNP litigation presents legal uncertainties involving Moderna, Roivant Sciences, and Pfizer.Some support2 reports
-
Roivant Sciences acquired Immunovant and established Vants as a focused subsidiary.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Roivant Sciences (United States) this week
News at the entities that move Roivant Sciences (United States) most-
Securities and Exchange Commission StructuralThe SEC is overseeing a stock offering by Alpha Modus Holdings, Inc., which began on October 1, 2026.Moves Roivant Sciences (United States)
-
FDA StructuralIndian products were subject to an FDA recall.Moves Roivant Sciences (United States)
-
SEC StructuralProShares filed a disclosure with the SEC regarding its Nasdaq-100 Dorsey Wright Momentum ETF.Moves Roivant Sciences (United States)
-
Citigroup TransactionalRoyal Bank of Canada, Citigroup, and Morgan Stanley issued price target and rating updates on August 27, 2026.Moves Roivant Sciences (United States)
-
Stifel TransactionalStifel established its firm in St. Louis.Moves Roivant Sciences (United States)
-
TD Cowen Mentioned togetherJim Cramer commented on L3Harris Technologies stock valuation as Goldman Sachs and TD Cowen cut price targets.Moves Roivant Sciences (United States)
Connections
The 18 strongest of 78, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Securities and Exchange Commission Structural
Roivant Sciences is subject to regulation and disclosure requirements enforced by the Securities and Exchange Commission.
-
FDA Structural
Roivant Sciences requires formal regulatory review and approval from the FDA for its drug products.
-
Pfizer Transactional
Pfizer and Roivant are engaged in LNP litigation and operate under a formal drug licensing and supply agreement.
-
SEC Structural
Roivant Sciences is subject to formal regulatory oversight by the SEC regarding insider trading disclosures.
-
Citigroup Transactional
Citigroup evaluated Roivant Sciences by raising its target price and issuing a buy rating.
-
Leerink partners Mentioned together
Leerink partners provides financial analysis and price targets for Roivant Sciences.
-
Fifth Third Bancorp Transactional
Fifth Third Bancorp increased its investment position in Roivant Sciences.
-
Stifel Transactional
Stifel initiated market coverage of Roivant Sciences and assigned a Buy rating.
Show all 18 connections
-
Jefferies Financial Group Transactional
Jefferies Financial Group provided buy ratings and price targets for Roivant Sciences.
-
niu Operational
A is involved in a Phase III study conducted by Roivant Sciences (B).
-
LPP Structural
Roivant Sciences is conducting a registrational trial for LPP.
-
Europe Shared context
Roivant Sciences views Europe as a potential market for its successful drug candidates.
-
Nasdaq Shared context
Roivant Sciences is a company whose stock is listed and traded on the Nasdaq exchange.
-
MarketBeat Mentioned together
MarketBeat, as a financial information aggregator, reports consensus ratings and target prices for Roivant Sciences.
-
TD Cowen Mentioned together
TD Cowen issued buy rating reports regarding Roivant Sciences.
-
Bank of America Mentioned together
Bank of America issued a neutral rating regarding Roivant Sciences.
-
Morgan Stanley Transactional
Investment activity between Morgan Stanley and Roivant Sciences, including stake reductions and increases.
-
Pharming Group (Netherlands) Mentioned together
The entities are co-mentioned in the context of being compared healthcare companies.
History
Events by the month they beganOctober 2026
2 eventsSeptember 2026
5 events- Ramaswamy's financial profile and business interests in Roivant Sciences are being reported amid the Ohio gubernatorial race.
- Acton's political rivals are contrasting her wealth sources, which stem from a company she founded that is generating wealth.
- Roivant Sciences licensed a drug from Pfizer for regulatory approval.
- Roivant Sciences identifies a potential market for its successful drug candidate in Europe.
- A drug developed by Roivant/Priovant Therapeutics received FDA approval for the treatment of dermatomyositis.
August 2026
2 eventsShow 2 earlier months
July 2026
2 eventsJune 2026
8 events- Analyst firm Leerink partners raised the price target for Roivant based on share count forecast on August 13, 2025.
- Roivant Sciences received a buy rating and price targets from Jefferies Financial Group.
- Roivant filed a 10-Q statement with the SEC on August 12, 2025, while its stock was sliding against a marginally down S&P 500.
- Roivant reported financial results from Basel, Switzerland, and hosted a conference call in London.
- Goldman Sachs resumed coverage of Pulmovant, a Roivant subsidiary, with a 'Buy' rating.
- Eric Venker sold shares worth $1,145,000 of Roivant Sciences on June 25, 2025.
- Ongoing LNP litigation presents legal uncertainties involving Moderna, Roivant Sciences, and Pfizer.
- Roivant Sciences acquired Immunovant and established Vants as a focused subsidiary.